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Summary
Background  and  purpose:  We  have  reported  that  matrix  metalloproteinase-2  (MMP-2)  increased
in acute  heart  failure  (AHF)  and  better  prognosis  was  found  in  patients  with  greater  reduction
in MMP-2.  We  assessed  whether  a  statin  decreased  MMP-2  in  AHF.
Methods  and  results:  The  serum  MMP-2  levels  were  measured  on  admission  (Day  1),  Day  3,
Day 7,  and  Day  14  in  50  AHF  patients.  The  patients  were  randomized  to  either  atorvastatin
(n =  25)  or  control  group  (n  =  25).  Atorvastatin  (10—20  mg/day)  was  started  within  12  h  after
their admission  and  then  was  continued  for  two  weeks.  There  were  no  differences  in  the  serum
levels of  MMP-2  on  Day  1  between  atorvastatin  group  (1400.4  ±  318.6  ng/ml)  and  control  group
(1292.7 ±  384.7  ng/ml).  MMP-2  signiﬁcantly  decreased  in  both  groups  on  Day  3,  7,  and  14.  How-
ever, the  MMP-2  value  on  Day  3  compared  to  Day  1  was  observed  to  have  decreased  signiﬁcantly
in atorvastatin  group  (561.8  ±  235.1  ng/ml)  compared  to  control  group  (272.6  ±  270.6  ng/ml;
p =  0.001).  HF  events  which  were  deﬁned  as  death  from  HF,  readmission  to  hospital  for  HF,
or prolonged  hospital  stay  because  of  uncontrollable  HF,  occurred  more  in  control  group  than
in atorvastatin  group.  Kaplan—Meier  curves  showed  that  the  prognosis  of  HF  was  signiﬁcantly
better in  atorvastatin  group  as  c
Conclusion:  In  addition  to  conve
decrease  in  MMP-2  and  also  imp
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Introduction
Matrix  metalloproteinases  (MMPs)  play  an  important  role
as  a  biomarker  of  heart  failure  (HF)  and  they  are  also
one  of  the  key  mechanisms  in  the  progression  of  HF.  In
patients  with  chronic  HF,  the  presence  of  increased  serum
levels  of  MMP-2  [1]  and  MMP-9  [2]  has  been  reported.
In  acute  HF  (AHF)  patients,  it  was  also  reported  that
serum  levels  of  MMP-2  were  increased  on  admission  and
decreased  before  discharge  [3].  Biolo  et  al.  concluded
that  the  increase  in  extracellular  matrix  turnover  may  be
associated  with  an  acceleration  of  pathological  myocar-
dial  remodeling  in  patients  with  AHF  [3].  The  decrease
in  MMP-2  might  mean  a  reduction  of  myocardial  remod-
eling.  We  found  that  MMP-2  had  already  decreased  after
3  days  due  to  the  improvement  in  HF  with  conventional
therapy.  Furthermore,  a  rapid  decline  in  the  MMP-2  lev-
els  with  the  initial  therapy  may  thus  play  an  important
role  in  obtaining  a  better  clinical  outcome  in  patients
with  AHF  [4].  The  pharmacological  modiﬁcation  of  MMP-
2  may  therefore  be  beneﬁcial  for  the  treatment  of  AHF
patients.
Statins  have  been  thought  to  be  beneﬁcial  for  the  pre-
vention  of  atherothrombosis  and  the  primary  and  secondary
prevention  of  coronary  events  due  to  their  lipid-lowering
actions,  which  reduce  the  plaque  burden  and  stabilize
vulnerable  plaques.  It  was  reported  that  early  statin  initi-
ation  can  lead  to  a  decrease  in  the  risk  of  fatal  events  in
coronary  artery  disease  patients  [5].  In  addition  to  these
actions,  statins  also  have  pleiotropic  effects  [6],  includ-
ing  anti-inﬂammatory  [7],  anti-hypertrophic,  anti-ﬁbrotic
[8],  and  anti-oxidant  effects  [9].  The  majority  of  these
effects  can  target  important  components  of  the  complex
physiopathology  of  HF  [10]. Many  nonrandomized  studies,
and  several  small,  prospective  and  retrospective  studies
have  therefore  suggested  the  use  of  statins  to  be  associ-
ated  with  a  better  outcome  in  patients  with  chronic  HF
[11,12].  In  these  studies,  statins  demonstrated  several  bio-
logical  and  clinical  effects  in  patients  with  chronic  HF.
However,  the  effect  of  statins  in  AHF  has  not  yet  been
addressed.
The  inﬂammatory  response  increases  the  production  of
MMPs,  and  therefore  statins  may  affect  the  production  of
MMPs.  In  fact,  pravastatin  has  been  reported  to  decrease
the  serum  levels  of  MMP-2  [13]  and  the  coronary  sinus  levels
of  MMP-2  and  MMP-9  [14]  in  patients  with  acute  myocar-
dial  infarction.  Atorvastatin  also  signiﬁcantly  reduced  the
serum  levels  of  MMP-9  [15]  in  patients  with  acute  myocar-
dial  infarction.  However,  the  relationship  between  MMPs  and
statin  therapies  in  patients  with  HF,  especially  AHF,  remains
obscure.
According  to  two  recently  published  randomized,  dou-
ble  blind,  placebo-controlled  trials,  CORONA  and  GISSI-HF
study,  patients  with  HF  did  not  beneﬁt  from  rosuvas-
tatin  therapy  regarding  the  overall  prognosis  [16,17].
These  studies  were  conducted  using  patients  with  chronic
HF,  however,  the  effect  of  the  early  administration
of  statin  in  patients  with  AHF  is  not  clear.  There-
fore,  the  present  randomized,  controlled  study  evaluated
whether  atorvastatin  decreased  MMP-2  quickly  during  treat-
ment  and  thus  improved  the  prognosis  in  patients  with
AHF.
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ethods
ubjects
ifty  patients  with  AHF  who  were  admitted  to  the  inten-
ive  care  unit  of  Chiba  Hokusoh  Hospital,  Nippon  Medical
chool  between  December  2007  and  February  2009  were
ntered  in  this  prospective  study.  AHF  was  deﬁned  as  either
ew-onset  HF  or  decompensation  of  chronic  HF  with  symp-
oms  that  were  sufﬁcient  to  warrant  hospitalization  [18].
F  was  diagnosed  based  on  the  Framingham  criteria  for  a
linical  diagnosis  of  HF,  based  on  the  satisfaction  of  2  major
riteria  or  1  major  and  2  minor  criteria  [19]. All  patients
ad  a New  York  Heart  Association  (NYHA)  functional  class  of
ither  III  or  IV.  The  patients  were  excluded  if  they  had  acute
oronary  syndrome,  renal  failure  (serum  levels  of  creatinine
3.0  mg/dl),  acute  infection,  chronic  liver  disease,  malig-
ancy,  or  connective  tissue  diseases.  The  patients  were  also
xcluded  if  they  had  been  taking  lipid-lowering  agents  prior
o  admission.
rocedures
he  AHF  patients  were  randomized  to  either  the  ator-
astatin  or  control  group.  Atorvastatin  (20  mg  per  day,
nly  two  cases  were  10  mg/day)  was  begun  within  12  h
fter  admission,  and  continued  for  two  weeks.  There  were
o  limitations  in  HF  therapy  except  statin  use,  and  the
trategy  of  the  treatment  was  chosen  by  each  of  the
octors.  All  efﬁcacious  treatments  for  AHF  [e.g.  diuretic
rugs,  carperitide,  nitroglycerin,  angiotensin-converting
nzyme  inhibitors  (ACE-I)/angiotensin  II  receptor  blocker
ARB),  and  -blockers]  were  recommended  for  patient
se.
erum  MMP-2  measurements
he  blood  samples  were  collected  into  tubes  containing
thylenediaminetetraacetic  acid  and  centrifuged  immedi-
tely  within  30  min  of  admission  (Day  1),  on  hospital  days  3
Day  3),  7  (Day  7),  and  14  (Day  14).  The  serum  levels  of  MMP-
 were  measured  at  each  sampling  point.  The  serum  levels
f  MMP-2  were  measured  by  an  enzyme-linked  immunosor-
ent  assay  (ELISA)  according  to  the  manufacturer’s  protocol
Special  Reference  Laboratory:  SRL,  Tokyo,  Japan).  The  nor-
al  ranges  of  values  published  by  the  manufacturer  were  as
ollows:  MMP-2,  570  ±  118  ng/ml.  The  serum  levels  of  MMP-
 and  MMP-2  deﬁned  as  changes  in  MMP-2  from  Day  1  to
ay  3  were  compared  between  the  groups.  The  serum  levels
f  total  cholesterol,  triglycerides,  low-density  lipoprotein
LDL)  cholesterol,  and  high-density  lipoprotein  (HDL)  choles-
erol  were  also  measured  using  an  enzyme  immunoassay  kit
SRL)  at  each  sampling  point.
In  addition,  we  compared  the  patient  characteristics,
ncluding  the  baseline  values  at  the  time  of  patient  admis-
ion  and  the  medications  prescribed  during  hospitalization,
n  two  groups  divided  by  the  value  of  MMP-2.  The  patients
ere  divided  into  the  two  groups  based  on  whether  the
MMP-2  was  above  or  below  the  median  value.
Serum  MMP-2  samples  were  obtained  from  all  50  patients
n  Day  1,  Day  3,  and  Day  7,  and  from  47  patients  before
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ischarge  (samples  from  1  patient  were  not  collected  and  2
atients  died).
easurement  of  left  ventricular  ejection  fraction
ll  patients  underwent  transthoracic  echocardiography  at
he  time  of  patient  admission  and  after  HF  was  stabilized
Sonos  5500,  Hewlett  Packard,  Palo  Alto,  CA,  USA  or  Vivid
,  GE  Yokokawa  Medical,  Tokyo,  Japan).  The  left  ventricular
jection  fraction  (LVEF)  was  calculated  using  the  Teichholz
ethod  or  Simpson’s  method.
MPs  and  HF  events
he  patients  were  clinically  followed  up  for  1.5  years  (a
edian  of  338.4  ±  207.7  days)  at  a  routine  outpatient  clinic.
F  events  were  deﬁned  as  death  from  HF,  readmission  to
ospital  for  HF,  or  prolonged  hospital  stay  because  of  uncon-
rollable  HF  persisting  for  over  6  months.  Uncontrollable  HF
as  deﬁned  as  a  need  for  continuous  infusion  of  inotropic
gents  to  treat  HF.  The  relationship  between  HF  events  and
tatin  therapy  was  investigated.
tatistical  analysis
ll  numerical  data  were  expressed  as  the  mean  ±  standard
eviation.  The  comparisons  of  all  proportions  were  per-
ormed  using  a  chi-square  analysis.  The  change  in  MMP-2
ver  time  after  admission  was  tested  by  one-way  analysis
f  variance  (ANOVA)  by  repeated  measures.  When  a  signif-
cant  change  was  observed,  the  levels  at  individual  time
oints  were  compared  using  Fisher’s  PLSD  post  hoc  tests.
ann—Whitney  analysis  was  used  to  compare  mean  values
etween  the  statin  group  and  the  control  group.  A  p-value
f  less  than  0.05  was  deﬁned  to  be  statistically  signiﬁ-
ant.  Signiﬁcant  medications  for  reduction  of  MMP-2  were
etermined  by  a  multivariate  logistic  regression  model.  The
vent-free  rates  between  the  groups  were  analyzed  using
aplan—Meier  survival  curves  according  to  the  statin  ther-
py,  and  signiﬁcant  differences  were  calculated  using  the
og-rank  test.
All  data  were  statistically  analyzed  using  the  StatView
 software  program  for  Windows  (SAS  Institute,  Cary,  NC,
SA),  and  SPSS  14.0J  for  Windows  (SPSS  Japan  Institute,
okyo,  Japan).
thical  concerns
he  institutional  review  board  at  Chiba  Hokusoh  Hospital,
ippon  Medical  School  approved  the  study  protocol.  All
atients  provided  their  written  informed  consent  to  partic-
pate  in  this  study.
esults
atient  characteristicsifty  patients  with  AHF  were  enrolled  and  randomized  to
ither  the  atorvastatin  (n  =  25)  or  control  group  (n  =  25).
he  patient  cohort  included  66%  male  subjects  with  a
f
r
ﬁA.  Shirakabe  et  al.
ean  age  of  72.4  ±  10.9  years.  Twenty-seven  (54%)  of  the
atients  had  ischemic  heart  disease,  and  23  (46%)  had  non-
schemic  heart  diseases,  including  dilated  cardiomyopathy
n  =  3),  hypertensive  heart  disease  (n  =  10),  valvular  disease
n  =  7),  and  tachycardia-induced  cardiomyopathy  (n  =  3).  The
ajority  of  patients  were  in  NYHA  class  IV  (84%),  and  the
verage  LVEF  determined  by  transthoracic  echocardiogra-
hy  at  the  time  of  patient  admission  was  35.1  ±  15.6%.  All
f  the  patients  received  intravenous  loop  diuretics  dur-
ng  the  acute  phase.  Nitroglycerin  and  carperitide  were
dministered  in  84.0%  and  84.0%  of  patients,  respectively.
n  contrast,  dopamine  and  dobutamine  were  used  in  18.0%
nd  28.0%  of  patients,  respectively.  ACE-I  or  ARB  were
aken  by  30  patients  (60.0%),  while  -blockers  had  already
een  taken  by  13  (26.0%)  patients  at  the  time  of  admis-
ion.
Table  1  compares  the  backgrounds  of  the  patients  in
he  statin  and  control  groups.  The  patients’  pulse  rates
t  the  time  of  admission  were  signiﬁcantly  higher  in  the
tatin  group  (129.1  ±  20.2  beat/min)  than  in  the  control
roup  (109.2  ±  21.5  beat/min),  and  systolic  blood  pressure
as  also  higher  in  the  statin  group  (180.1  ±  35.5  mmHg)
han  in  the  control  group  (147.5  ±  33.2  mmHg).  The  other
atient  information  was  not  different  between  the  two
roups.
erum  lipid  measurements
able  2  summarizes  the  changes  in  serum  lipid  levels
etween  the  patients  in  the  statin  and  control  groups.  The
erum  levels  of  total  cholesterol  and  LDL  cholesterol  on
ays  3,  7,  and  14  were  signiﬁcantly  decreased  in  com-
arison  to  the  value  on  Day  1  in  the  statin  group,  but
hese  values  were  not  decreased  in  the  control  group.  On
ay  14,  the  serum  levels  of  LDL  cholesterol  were  signiﬁ-
antly  lower  in  the  statin  group  compared  to  the  control
roup,  however  total  cholesterol  was  not  statistically  dif-
erent  between  the  statin  and  control  group.  The  serum
evels  of  triglycerides  did  not  change  over  this  time  course,
nd  were  not  different  between  the  statin  and  control
roups.
MP-2  and  statin  therapy
o  differences  were  observed  in  the  serum  lev-
ls  of  MMP-2  on  Day  1  between  the  atorvastatin
roup  (1400.4  ±  318.6  ng/ml)  and  the  control  group
1292.7  ±  384.7  ng/ml).  Furthermore,  serum  levels  of  MMP-
 were  not  statistically  different  at  each  sampling  point
Table  3).
MMP-2  was  signiﬁcantly  decreased  in  the  atorvastatin
nd  control  groups  on  Day  3,  Day  7,  and  Day  14  com-
ared  with  Day  1  (p  <  0.001;  Fig.  1).  Decreases  in  MMP-2
n  Day  3  compared  to  Day  1  (MMP-2)  were  signiﬁcantly
reater  in  the  atorvastatin  group  (561.8  ±  235.1  ng/ml)  than
n  the  control  group  (272.6  ±  270.6  ng/ml;  p  =  0.001)  (Fig.  1,
able  3).The  results  of  the  multivariate  logistic  regression  model
or  MMP-2  found  that  the  speciﬁc  medication  for  the
eduction  of  MMP-2  was  statin  (odds  ratio:  4.231,  95%con-
dence  interval:  1.041—17.204;  p  =  0.044)  (Table  4).  In
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Table  1  Comparison  of  the  patient  background  in  the  statin  group  and  control  group.
Statin  group  (n  =  25)  Control  group  (n  =  25)  p-Value
Age  (years)  71.1  ±  9.4  73.6  ±  12.4  0.429
Gender (male/female)  15/10  18/7  0.551
Type (new  onset/worsening)  15/10  15/10  0.387
Etiology (ischemia/non-ischemia)  14/11  13/12  0.999
NYHA (III/IV)  3/22  5/20  0.702
BUN (mg/dl) 22.9  ±  9.9  29.6  ±  19.3  0.132
Creatinine (mg/dl) 1.09  ±  0.45 1.26  ±  0.49  0.229
Total bilirubin  (mg/dl) 0.69  ±  0.30 0.83  ±  0.51 0.253
Urinary acid  (mg/dl) 7.25  ±  1.70 7.33  ±  2.41 0.901
Sodium (mmol/l) 139.6  ±  2.4 139.3  ±  3.9 0.730
Potassium  (mmol/l)  4.21  ±  0.56  4.37  ±  0.65  0.342
Hemoglobin  (g/dl)  14.1  ±  2.3  13.2  ±  2.4  0.263
Systolic blood  pressure  (mmHg)  180.1  ±  35.5  147.5  ±  33.2  0.003
Pulse rate  (beats/min)  129.1  ±  20.2  109.2  ±  21.5  0.001
LVEF (%)  32.8  ±  11.5  37.4  ±  18.9  0.310
Total admittance  (days)  27.8  ±  20.1  38.2  ±  44.9  0.300
Medication
Furosemide  (y/n)  25/0  25/0  0.999
Nitroglycerin  (y/n)  24/1  18/7  0.054
Carperitide  (y/n)  22/3  20/5  0.415
Dopamine (y/n)  2/23  7/18  0.415
Dobutamine  (y/n)  3/22  11/17  0.289
ACE-I/ARB (y/n) 17/8  13/12  0.387
-blocker (y/n)  5/20 8/17  0.753
Spironolactone  (y/n) 19/6  15/10  0.363
Past medical  history
Hypertension  (y/n) 19/6  17/8  0.753
Diabetes mellitus  (y/n) 11/14 11/14  0.999
Dyslipidemia  (y/n) 14/11 10/15 0.396
(y/n), (yes/no); NYHA, New York Heart Association; BUN, blood urea nitrogen; LVEF, left ventricular ejection fraction measured by
echocardiogram on admission; ACE-I, angiotensin converting enzyme-inhibitor; ARB, angiotensin II receptor blocker; p-value for between-
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addition,  systolic  blood  pressure  at  admission  was  higher
in  the  high  MMP-2  group  (176.2  ±  31.7  mmHg)  than  in
the  low  MMP-2  group  (151.4  ±  39.9  mmHg).  However,  the
other  patient  information  including  the  patients’  charac-
teristics,  baseline  values  on  admission,  and  medications
prescribed  during  hospitalization  except  for  statins  were
not  different  between  high  and  low  MMP-2  groups
(Table  5).
Statin  therapy  and  HF  events
Patients  were  clinically  followed  up  at  a  routine  outpa-
tient  clinic  for  1.5  years  (a  median  of  338.4  ±  207.7  days).
HF  events  occurred  in  14  of  the  50  patients  (28.0%),  and
included  6  deaths  from  HF,  6  readmissions  to  hospital  for  HF,
and  2  prolonged  hospital  stays  because  of  uncontrollable  HF
persisting  for  over  6  months.  The  HF  events  occurred  more
in  the  control  group  (n  =  10;  4  cardiac  deaths,  4  readmis-
sions  to  hospital  for  HF,  and  2  uncontrollable  HF)  than  in  the
atorvastatin  group  (n  =  4;  2  cardiac  deaths,  2  readmissions  to
hospital  for  HF).  Kaplan—Meier  curves  showed  that  the  prog-
nosis  of  HF  was  signiﬁcantly  better  in  the  atorvastatin  group
t
n
a
sompared  with  the  control  group  (log-rank  test,  p  =  0.037)
Fig.  2).
iscussion
tatin  therapy  and  MMPs
o  our  knowledge,  this  is  the  ﬁrst  report  on  the  effect
f  statin  therapy  on  MMP-2  in  patients  with  AHF.  These
esults  suggested  that  statin  therapy  may  be  a  poten-
ial  novel  treatment  strategy  for  patients  with  AHF.  The
se  of  statins  may  therefore  provide  beneﬁcial  effects  in
atients  with  AHF  in  addition  to  lipid-lowering  effects.
everal  studies  have  demonstrated  that  the  administra-
ion  of  statins  resulted  in  decreased  MMP  levels  in  human
arotid  plaques  [20], vascular  endothelial  cells  [21], and
acrophages  [22]. Atorvastatin  signiﬁcantly  reduced  the
erum  levels  of  MMP-9  [15], and  pravastatin  attenuated
he  increased  serum  levels  of  MMP-2  [13]  and  the  coro-
ary  sinus  levels  of  MMP-2  and  MMP-9  [14]  in  patients  with
cute  myocardial  infarction.  These  ﬁndings  indicated  that
tatins  may  modulate  cardiac  MMP-2  and  MMP-9  production
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Table  2  Serum  lipid  levels  in  the  statin  group  and  control  group.
Statin  group  (n  =  25)  Control  group  (n  =  25)  p-Value
Total  cholesterol  (mg/dl)
Day  1  207.3  ±  61.2  178.2  ±  55.3  0.105
Day 3  175.8  ±  46.5* 157.3  ±  51.9* 0.183
Day 7  157.6  ±  23.4* 172.6  ±  54.1  0.461
Day 14 141.2  ±  23.8* 188.1  ±  55.8  0.128
Triglycerides  (mg/dl)
Day  1 129.1 ±  102.4  119.0 ±  191.0  0.869
Day 3 99.1 ±  47.9  86.2 ±  46.4  0.254
Day 7  111.1  ±  46.2  110.3  ±  56.2  0.705
Day 14  107.5  ±  55.9  111.0  ±  46.2  0.516
LDL cholesterol  (mg/ml)
Day  1 129.9  ±  55.9  113.0  ±  37.4  0.541
Day 3  110.6  ±  38.9* 106.2  ±  39.5  0.960
Day 7  95.6  ±  20.3* 115.3  ±  42.1  0.123
Day 14  78.3  ±  22.7* 128.2  ±  41.1* <0.001
HDL cholesterol  (mg/ml)
Day  1  51.6  ±  14.2  41.4  ±  14.0  0.014
Day 3  45.4  ±  11.1* 33.9  ±  13.4* 0.002
Day 7 39.8  ±  9.2* 35.2  ±  11.1* 0.117
Day 14  41.4  ±  11.1* 33.4  ±  10.9* 0.018
LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Day 1, within 30 min of admission; Day 3, on hospital day 3; Day 7, on hospital day 7.
Day 14, on hospital day 14.
*
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ip < 0.05 vs. Day 1 for all sampling data.
n  patients  with  acute  myocardial  infarction,  which  may
ccur  through  its  anti-inﬂammatory  effects.  Previous  stud-
es  also  reported  that  statins  suppressed  the  inﬂammatory
rocess  in  patients  with  HF  [7,8]. HF  was  associated  with
ncreased  levels  of  proinﬂammatory  cytokines  that  exerted
egative  inotropic  effects  and  induced  apoptosis  in  car-
iac  myocytes.  Statins  may  therefore  inhibit  the  production
f  MMPs  via  anti-inﬂammatory  effects,  such  as  in  the
nhibition  of  macrophage  chemotaxis,  and  the  reduction
c
s
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p
Table  3  Serum  levels  of  MMP-2  and  BNP  in  the  statin  group  and  c
Statin  group  (n  =  25)  
MMP-2  (ng/ml)
Day  1  1400.4  ±  318.6  
Day 3  838.5  ±  236.9  
Day 7  1015.8  ±  334.6  
Day 14  969.1  ±  272.8  
MMP-2 561.8  ±  235.1  
BNP (pg/ml)
Day  1  773.3  ±  463.0  
Day 3 372.3  ±  332.9  
Day 7 467.2 ±  430.8  
Day 14 354.3 ±  387.8  
BNP 338.0 ± 971.8  
MMP, matrix metalloproteinase; BNP, brain natriuretic peptide.
Day 1, within 30 min of admission; Day 3, on hospital day 3; Day 7, on h
in MMP-2 and BNP from Day 1 to Day 3; p value for between-group comf  cytokine  and  growth  factor  levels  [23]. However,  in
he  present  study,  some  inﬂammatory  markers  did  not
ecrease  in  the  statin  group  in  comparison  to  the  control
roup.  The  lack  of  statistical  signiﬁcance  of  the  changes
n  these  inﬂammatory  markers  between  the  statin  and
ontrol  groups  may  be  due  to  the  characteristics  of  the
tudy  patients.  On  the  other  hand,  other  pathways  might
ediate  the  statin-induced  decrease  in  MMPs  levels.  One
lausible  mechanism  is  statin-induced  increase  in  nitric
ontrol  group.
Control  group  (n  =  25)  p-Value
1292.7  ±  384.7  0.221
1020.2  ±  404.8  0.114
1102.4  ±  334.4  0.308
1038.1  ±  290.7  0.212
272.6  ±  270.6  0.001
1292.2  ±  1359.2  0.455
825.8  ±  1023.8  0.252
834.0  ±  1333.4  0.628
716.5 ±  1087.9  0.245
466.3  ±  1013.3  0.884
ospital day 7; Day 14, before discharge; delta means the change
parisons.
Immediate  administration  of  atorvastatin  decreased  the  serum  MMP-2  level  379
Table  4  Multivariate  analysis  for  indicating  MMP-2.
Medications  OR  95%CI  p-Value
Furosemide  0.000  0.000—  1.000
Nitroglycerin  3.240  0.435—24.136  0.251
Carperitide  3.029  0.308—29.782  0.342
Dopamine 0.801  0.084—7.633  0.847
Dobutamine 0.506  0.079—3.239  0.472
ACE-I/ARB 1.252  0.234—6.700 0.793
-blocker  1.489  0.312—7.099 0.617
Spironolactone 0.253  0.044—1.458 0.124
Statin 4.231  1.041—17.204  0.044
rval; MMP, matrix metalloproteinase; OR, odds ratio; CI, conﬁdence inte
II receptor blocker.oxide  bioavailability  [24]  as  endothelial  nitric  oxide  syn-
thase  gene  transfer  has  been  demonstrated  to  decrease
MMP  activities  [25]. However,  the  exact  mechanisms  by
which  statins  may  be  involved  in  the  regulation  of  matrix
m
d
o
Table  5  Patient  characteristics  and  MMP-2.
High  MMP-2  group  (n
Age  (years)  73.0  ±  10.1  
Gender (male/female)  18/7  
Type (new  onset/worsening)  12/13  
Etiology (ischemia/non-ischemia)  12/13  
NYHA (III/IV)  2/23  
BUN (mg/dl)  24.7  ±  11.8  
Creatinine (mg/dl) 1.15  ±  0.44  
Total bilirubin  (mg/dl) 0.72  ±  0.29
Urinary acid  (mg/dl) 6.84  ±  1.61
Sodium (mmol/l) 140.3  ±  2.6
Potassium (mmol/l) 4.2  ±  0.6
Hemoglobin  (g/dl) 13.7  ±  2.3
BNP (pg/ml) 1034.4  ±  968.1
Systolic blood  pressure  (mmHg) 176.2  ±  31.7
Pulse (beats/min) 124.5  ±  28.3  
LVEF (%)  on  admission  35.4  ±  13.5  
Total admittance  (days)  26.3  ±  16.9  
Medication
Furosemide  (y/n)  25/0  
Nitroglycerin  (y/n)  23/2  
Carperitide  (y/n)  22/3  
Dopamine (y/n)  2/23  
Dobutamine  (y/n)  3/22  
ACE-I/ARB (y/n)  17/8  
-blocker (y/n)  7/18  
Spironolactone  (y/n)  16/9  
Statin (y/n)  17/8  
Past medical  history
Hypertension  (y/n)  19/6  
Diabetes mellitus  (y/n)  10/15  
Dyslipidemia  (y/n)  11/14  
MMP, matrix metalloproteinase; high MMP-2 means decrease more th
(y/n), (yes/no); NYHA, New York Heart Association; BUN, blood urea
ejection fraction measured by echocardiogram on admission; ACE-I, ang
blocker. p value for between-group comparisons.ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensinetalloproteinases  in  humans  need  to  be  further  eluci-
ated.
It  has  been  reported  that  statins  inhibited  the  activities
f  several  species  of  myocardial  MMPs  in  animal  models  of
 =  25) Low  MMP-2  group  (n  =  25)  p-Value
71.7  ±  11.9  0.684
15/10  0.551
8/17  0.387
15/10  0.571
6/19  0.247
27.8  ±  18.7  0.488
1.19  ±  0.51  0.752
0.80  ±  0.52  0.461
7.71  ±  2.39 0.151
138.6  ±  3.6  0.066
4.4  ±  0.6 0.275
13.8  ±  2.4 0.761
1031.0  ±  1124.6 0.991
151.4  ±  39.9 0.019
114.6  ±  16.5  0.138
34.8  ±  17.8  0.881
39.7  ±  45.9  0.178
25/0  0.999
19/6  0.247
22/3  0.999
5/20  0.415
7/18  0.289
13/12  0.387
6/19  0.999
18/7  0.762
8/17  0.024
17/8  0.753
12/13  0.776
13/12  0.551
an 420 ng/ml; low MMP-2 means decrease less than 420 ng/ml,
 nitrogen; BNP, brain natriuretic peptide; LVEF, left ventricular
iotensin-converting enzyme inhibitor; ARB, angiotensin II receptor
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Figure  1  Time-dependent  changes  in  serum  matrix  metallo-
proteinase  (MMP)-2  after  treatment  for  acute  heart  failure.  The
serum  level  of  MMP-2  signiﬁcantly  (p  <  0.001)  decreased  in  the
atorvastatin  and  control  groups  on  Day  3  from  Day  1  and  there-
after  the  level  reached  a  plateau.  Furthermore,  decreases  in
MMP-2  on  Day  3  and  7  compared  to  Day  1  were  signiﬁcantly
greater  in  the  atorvastatin  group  than  in  the  control  group.  Val-
ues are  expressed  as  the  mean  ±  SD.  Day  1,  within  30  min  of
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odmission;  Day  3,  on  hospital  day  3;  Day  7,  on  hospital  day  7;
ay 14,  on  hospital  day  14.
F.  Hayashidani  et  al.  reported  that  ﬂuvastatin  may  improve
V  remodeling  and  functioning  through  the  attenuation  of
ncreased  MMP-2  and  MMP-13  activity  in  a  murine  model
f  post-infarction  HF  [26]. Ichihara  et  al.  also  reported
hat  pravastatin  signiﬁcantly  attenuated  increases  in  the
ctivities  of  MMP-2  and  MMP-9  in  the  left  ventricle  that
ccompany  hypertensive  HF  in  a  rat  model  [27]. Further-
ore,  statin  treatment  improved  LV  remodeling  and  function
fter  myocardial  infarction  by  directly  attenuating  MMP
ctivities  in  mice  and  rats.
We  supposed  in  a  previous  study  that  the  decompensation
tate  of  AHF  may  accelerate  myocardial  remodeling  due  to
p=0.037
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igure  2  Kaplan—Meier  curves  for  statin  therapy.
aplan—Meier  curves  showed  that  the  prognosis  of  heart
ailure  was  signiﬁcantly  better  in  the  atorvastatin  group
ompared  with  the  control  group  (log-rank  test,  p  =  0.037).
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he  increase  in  MMP-2  [4].  Statins  may  attenuate  LV  remodel-
ng  through  the  direct  inhibition  of  MMP-2  production  in  the
HF  ventricle.  Therefore,  the  early  administration  of  ator-
astatin  may  preserve  cardiac  acute  remodeling  by  reducing
MP-2  activity  in  patients  with  AHF.  In  the  present  study,
he  MMP-2  value  on  Day  3  compared  to  Day  1  was  found
o  have  decreased  signiﬁcantly  more  in  the  atorvastatin
roup  than  in  the  control  group.  However,  we  were  unable
o  elucidate  the  mechanism  by  which  statins  reduce  MMP-2
roduction.
On  the  other  hand,  there  was  no  difference  in  the  changes
n  the  levels  of  B-type  natriuretic  peptide  (BNP)  after  three
ays  between  the  two  groups.  When  the  heart  experiences
olume  expansion  or  pressure  overload,  the  resulting  wall
tress  initiates  the  synthesis  of  pro-BNP  in  the  ventricular
nd  atrial  myocardium  [28]. Pro-BNP,  BNP  and  N-terminal
NT)-pro-BNP  can  be  detected  in  the  plasma.  Among  the
hree  molecular  forms,  serum  levels  of  BNP  and  NT-pro-BNP
ere  thought  to  be  inﬂuenced  by  ventricular  end  diastolic
ressure  and  LVEF  in  patients  with  chronic  HF  [29,30].  In
he  present  study,  it  is  difﬁcult  to  speculate  regarding  the
eason  why  statins  did  not  signiﬁcantly  decrease  the  serum
evels  of  BNP.  As  one  possibility,  statins  might  be  able  to  pre-
erve  cardiac  acute  remodeling  by  reducing  MMP-2  activity,
ut  might  not  be  able  to  reduce  the  volume  expansion  and
mprove  the  systolic  function  during  the  acute  phase.
tatins  and  prognosis
he  mortality  was  reduced  in  patients  who  were  receiving
tatins  according  to  a  retrospective  analysis  of  statin  use
n  HF  randomized  clinical  trials  [11]. Statins  also  improved
he  patient  mortality  and  reduced  HF  admission  in  retro-
pective  cohort  studies  of  statin  use  in  patients  with  HF  [8].
igh  doses  of  atorvastatin  can  prevent  the  re-hospitalization
f  HF  patients,  and  simvastatin  improved  the  mortality  of
atients  with  a  history  of  HF  according  to  a  subgroup  anal-
sis  of  a  randomized  study  in  patients  with  stable  coronary
isease  [12]. A  recent  report  conducted  a  small  prospec-
ive  randomized  trial  of  110  patients  with  NYHA  class  III  HF
nd  LVEF  <  30%  to  either  atorvastatin  10  mg/day  or  no  statin
reatment.  At  the  one-year  follow-up  examination,  a  signif-
cantly  lower  mortality  rate  was  present  in  patients  taking
tatins,  which  appeared  to  be  associated  with  a  decrease  in
he  rate  of  sudden  cardiac  death  [31]. However,  according
o  recently  published  randomized,  double  blind,  placebo-
ontrolled  trials,  CORONA  and  GISSI-HF  study,  patients  with
F  did  not  beneﬁt  from  a  rosuvastatin  therapy  with  regard
o  the  overall  prognosis  [16,17].  In  another  recent  study,
tatin  use  was  signiﬁcantly  associated  with  decreased  all-
ause  mortality  [32]. Therefore,  it  remains  controversial
ith  regard  to  whether  statin  therapy  improves  the  prog-
osis  of  patients  with  chronic  HF.  In  addition,  all  of  these
tudies  were  conducted  in  patients  with  chronic  HF.
In  our  previous  study,  we  reported  that  a rapid  decline
n  the  MMP-2  levels  with  the  initial  therapy  may  induce
 deceleration  of  myocardial  remodeling  during  the  acute
hase,  and  thus  play  an  important  role  in  obtaining  a  bet-
er  clinical  outcome  in  patients  with  AHF  [4].  Furthermore,
n  the  present  study,  Kaplan—Meier  curves  showed  that  the
rognosis  (death  from  HF,  readmission  to  hospital  for  HF,  or
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RImmediate  administration  of  atorvastatin  decreased  the  ser
prolonged  hospital  stay  because  of  uncontrollable  HF  per-
sisting  for  over  6  months)  of  HF  was  signiﬁcantly  better
in  the  atorvastatin  group  compared  with  the  control  group
(log-rank  test,  p  =  0.037).  We  showed  that  the  early  admin-
istration  of  atorvastatin  decreased  the  MMP-2  level  to  a
greater  extent  in  patients  with  AHF,  and  also  might  improve
the  prognosis.  Therefore,  the  early  administration  of  statin
therapy  may  cause  a  deceleration  of  myocardial  remodeling
during  the  acute  phase,  and  thus  lead  to  a  better  prognosis.
Future  studies  will  be  required  to  determine  whether  the
immediate  administration  of  statins  improves  the  prognosis
of  patients  with  AHF.
Lipid  proﬁle  and  safety  parameters
The  lipid-lowering  effects  of  atorvastatin  are  well-
established  and  were  conﬁrmed  in  the  present  study.
Furthermore,  the  administration  of  atorvastatin  was  safe,
and  the  liver  enzymes  and  creatine  kinase  values  remained
within  the  normal  ranges  in  patients  receiving  atorvas-
tatin  therapy.  The  serum  levels  of  total  cholesterol  and
LDL  cholesterol  were  observed  to  gradually  decrease  in  the
statin  group,  and  the  lowest  values  were  reached  on  Day
14.  However,  the  MMP-2  level  had  already  decreased  on  Day
3  and  the  value  reached  a  plateau.  Serum  levels  of  MMP-
2  were  not  correlated  with  LDL  cholesterol  at  all  sampling
points,  and  changes  in  MMP-2  from  Day  1  to  Day  3,  Day  7,
and  Day  14  were  not  correlated  with  changes  in  LDL  choles-
terol.  Namely,  the  mechanism  of  MMP-2  lowering  by  statins
was  different  to  the  lipid-lowering  effect.
Study  limitations
There  were  several  limitations  associated  with  the  present
study.  The  main  limitation  was  the  small  number  of  patients
included  in  each  group.  Because  the  present  study  was
small,  its  ﬁndings  will  require  conﬁrmation  in  a  larger,  well-
controlled,  randomized  clinical  trial.  Second,  there  was  no
limitation  in  HF  therapy  except  statin  use,  and  the  strat-
egy  of  the  treatment  was  chosen  by  each  of  the  doctors.  All
efﬁcacious  treatments  for  AHF  (e.g.  diuretic  drugs,  carperi-
tide,  nitrate,  ACE-I,  -blockers)  were  recommended  for  use.
Therefore,  a  pharmacological  bias  occurred  between  both
groups,  but  was  not  statistically  signiﬁcant.  Third,  the  ator-
vastatin  dose  was  different,  namely  with  doses  of  either
10  mg  or  20  mg.  In  fact,  the  ﬁrst  two  cases  were  adminis-
tered  10  mg  to  conﬁrm  the  safety  for  AHF  patients.  Fourth,
only  MMP-2  was  evaluated,  and  other  MMPs  may  exert  dif-
ferent  effects  in  patients  with  AHF.  Furthermore,  the  tissue
concentrations  of  MMP-2  were  not  evaluated.  Despite  some
evidence  for  increased  tissue  MMPs  in  animal  models  of  HF,
data  concerning  the  dynamic  changes  of  tissue  MMPs  dur-
ing  the  acute  phase  of  HF  are  limited.  Previous  studies  have
demonstrated  that  the  myocardium  is  an  important  source  of
changes  in  plasma  concentrations  of  MMPs  in  acute  coronary
syndrome  [33]. Therefore,  the  present  study  considered  only
the  concentrations  of  circulating  MMP-2.  Fifth,  an  increase
in  MMP-2  may  accelerate  myocardial  remodeling,  however,
we  were  unable  to  determine  the  relationship  between
the  changes  in  the  left  ventricular  geometry,  including  the
left  ventricular  volume  and  MMP-2/MMP-2.  All  patientsMP-2  level  381
nderwent  transthoracic  echocardiography  at  the  time  of
dmission  and  after  HF  was  stabilized,  but  it  was  difﬁcult
o  compare  these  data  because  they  were  recorded  under
ifferent  conditions.  We  were  unable  to  record  the  dimen-
ions  accurately  in  the  emergency  setting  with  orthopnea.
ixth,  as  the  present  study  was  a single  center  study,  patient
ias  might  exist.  For  example,  systolic  blood  pressure  and
eart  rate  were  relatively  high  compared  with  other  HF  reg-
stries.  Furthermore,  the  etiology  of  HF  was  mixed,  however,
he  proportion  in  etiology  of  HF  did  not  differ  between  the
tatin  group  and  control  group.  Finally,  systolic  blood  pres-
ure  and  heart  rate  were  signiﬁcantly  higher  in  the  statin
roup  than  in  control  group,  although  the  other  patient
haracteristic  did  not  differ  between  the  two  groups.  High
ouble  product  might  accelerate  myocardial  remodeling  due
o  the  increase  in  MMP-2.  In  fact,  serum  levels  of  MMP-2  were
igher  in  the  atorvastatin  group  (1400.4  ±  318.6  ng/ml)  than
n  the  control  group  (1292.7  ±  384.7  ng/ml).  This  difference
n  baseline  values  might  inﬂuence  the  reduction  in  MMP-2.
In  conclusion,  in  addition  to  conventional  HF  therapy,
n  early  start  of  atorvastatin  administration  signiﬁcantly
ecreased  MMP-2  to  a  greater  extent,  and  improved  prog-
osis  in  patients  with  AHF.
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